biotech

Biointron is excited to announce our participation in Swiss Biotech Day 2025, taking place on May 5-6, 2025, in Basel, Switzerland.

These past few weeks, several antibody drug startups have progressed from the pre-seed stage to final funding rounds. In the pre-seed stage, the focus is on early research, often funded by founders, grants, or angel investors. As the company progresses to the seed stage, it seeks additional funding to validate its scientific concept and develop initial prototypes, attracting early-stage venture capital.

Antibody-drug conjugates (ADCs) have revolutionized the landscape of oncology by delivering targeted therapies that minimize damage to healthy cells while maximizing the impact on cancerous tissues. However, researchers and clinicians are now exploring the many therapeutic possibilities of ADCs in treating a variety of non-cancerous conditions such as autoimmune, infectious, neurological, cardiovascular, and metabolic diseases.

Antibody drugs in ophthalmology represent a significant advancement in treating various eye diseases. These biologics target specific proteins involved in pathological processes, such as vascular endothelial growth factor (VEGF), which plays a key role in conditions like age-related macular degenera

BIO 2024 in San Diego showcased biotech innovation. Biointron reports highlights on antibody discovery, engineering, and collaborations shaping the future of biologics.

CROs speed up drug development. Biointron demonstrates how its expertise in antibody discovery, expression, and characterization helps partners achieve faster results.